Segment Information

3 Months Ended

Dec. 31, 2019

14. Segment Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, as follows: (1) the Medical Device unit, which designs, develops and manufactures interventional medical devices, primarily for the peripheral vascular market; surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

Segment revenue, operating (loss) income, and depreciation and amortization, were as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2019			2018
Revenue:
Medical Device	$	17,404		$	17,258
In Vitro Diagnostics		5,212			4,983
Total revenue	$	22,616		$	22,241

Operating (loss) income:
Medical Device	$	(423	)	$	357
In Vitro Diagnostics		2,599			2,455
Total segment operating income		2,176			2,812
Corporate		(2,442	)		(2,100	)
Total operating (loss) income	$	(266	)	$	712

Depreciation and amortization:
Medical Device	$	1,455		$	1,388
In Vitro Diagnostics		110			116
Corporate		239			252
Total depreciation and amortization	$	1,804		$	1,756

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision-making process.